Close Menu

NEW YORK – Oppenheimer has initiated coverage of MDxHealth with an Outperform rating and a price target of €2 per share.

In a note to investors on Monday, analyst Kevin DeGeeter cited the investment bank's expectation that the US Centers for Medicare and Medicaid Services will likely issue a positive Local Coverage Determination in 2021 for the use of the company's SelectMDx prostate cancer diagnostic in men considering a biopsy for prostate cancer detection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.